Ying Huang
Stock Analyst at B of A Securities
(2.30)
# 2,515
Out of 4,708 analysts
38
Total ratings
51.85%
Success rate
7.94%
Average return
Main Sectors:
Stocks Rated by Ying Huang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $545 → $522 | $388.25 | +34.45% | 11 | Dec 19, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $72 | $90.82 | -20.72% | 8 | Feb 5, 2020 | |
| RDUS Radius Recycling | Maintains: Buy | $51 → $47 | $15.93 | +195.04% | 1 | Jul 25, 2018 | |
| RGNX REGENXBIO | Downgrades: Neutral | $64 → $80 | $7.59 | +954.02% | 3 | Jul 23, 2018 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | n/a | $2.19 | - | 2 | May 2, 2018 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $34 → $40 | $1.07 | +3,655.87% | 2 | Mar 8, 2018 | |
| BLUE bluebird bio | Maintains: Neutral | $3,700 → $4,360 | $9.12 | +47,707.02% | 1 | Feb 22, 2018 | |
| PBYI Puma Biotechnology | Maintains: Buy | $135 → $115 | $2.76 | +4,074.23% | 2 | Jan 24, 2018 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Underperform | n/a | $3.59 | - | 4 | Jan 5, 2018 | |
| BIIB Biogen | Maintains: Buy | $358 → $365 | $146.92 | +148.43% | 1 | Oct 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $33 | $2.56 | +1,191.59% | 1 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $380 | $1.82 | +20,836.64% | 1 | Jul 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $258.42 | - | 1 | Feb 1, 2017 |
Vertex Pharmaceuticals
Dec 19, 2024
Maintains: Buy
Price Target: $545 → $522
Current: $388.25
Upside: +34.45%
Gilead Sciences
Feb 5, 2020
Maintains: Neutral
Price Target: $70 → $72
Current: $90.82
Upside: -20.72%
Radius Recycling
Jul 25, 2018
Maintains: Buy
Price Target: $51 → $47
Current: $15.93
Upside: +195.04%
REGENXBIO
Jul 23, 2018
Downgrades: Neutral
Price Target: $64 → $80
Current: $7.59
Upside: +954.02%
Esperion Therapeutics
May 2, 2018
Downgrades: Underperform
Price Target: n/a
Current: $2.19
Upside: -
CytomX Therapeutics
Mar 8, 2018
Maintains: Buy
Price Target: $34 → $40
Current: $1.07
Upside: +3,655.87%
bluebird bio
Feb 22, 2018
Maintains: Neutral
Price Target: $3,700 → $4,360
Current: $9.12
Upside: +47,707.02%
Puma Biotechnology
Jan 24, 2018
Maintains: Buy
Price Target: $135 → $115
Current: $2.76
Upside: +4,074.23%
Ironwood Pharmaceuticals
Jan 5, 2018
Downgrades: Underperform
Price Target: n/a
Current: $3.59
Upside: -
Biogen
Oct 18, 2017
Maintains: Buy
Price Target: $358 → $365
Current: $146.92
Upside: +148.43%
Sep 22, 2017
Maintains: Buy
Price Target: $23 → $33
Current: $2.56
Upside: +1,191.59%
Jul 24, 2017
Initiates: Buy
Price Target: $380
Current: $1.82
Upside: +20,836.64%
Feb 1, 2017
Upgrades: Buy
Price Target: n/a
Current: $258.42
Upside: -